Dr. Adam J. Olszewski
Claim this profileRhode Island Hospital
Studies Lymphoma
Studies Mantle Cell Lymphoma
10 reported clinical trials
25 drugs studied
Area of expertise
1Lymphoma
t(11;14) positive
CCND1 positive
CD19 positive
2Mantle Cell Lymphoma
t(11;14) positive
CCND1 positive
Stage I
Affiliated Hospitals
Clinical Trials Adam J. Olszewski is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
AB-101 + Immunotherapy
for Non-Hodgkin's Lymphoma
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Recruiting1 award Phase 1 & 24 criteria
More about Adam J. Olszewski
Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Adam J. Olszewski has experience with
- Rituximab
- Cyclophosphamide
- SGR-1505
- AB-101
- Mosunetuzumab
- Lenalidomide
Breakdown of trials Adam J. Olszewski has run
Lymphoma
Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam J. Olszewski specialize in?
Adam J. Olszewski focuses on Lymphoma and Mantle Cell Lymphoma. In particular, much of their work with Lymphoma has involved t(11;14) positive patients, or patients who are CCND1 positive.
Is Adam J. Olszewski currently recruiting for clinical trials?
Yes, Adam J. Olszewski is currently recruiting for 6 clinical trials in Providence Rhode Island. If you're interested in participating, you should apply.
Are there any treatments that Adam J. Olszewski has studied deeply?
Yes, Adam J. Olszewski has studied treatments such as Rituximab, Cyclophosphamide, SGR-1505.
What is the best way to schedule an appointment with Adam J. Olszewski?
Apply for one of the trials that Adam J. Olszewski is conducting.
What is the office address of Adam J. Olszewski?
The office of Adam J. Olszewski is located at: Rhode Island Hospital, Providence, Rhode Island 02903 United States. This is the address for their practice at the Rhode Island Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.